<DOC>
	<DOCNO>NCT02667925</DOCNO>
	<brief_summary>The treatment advance ovarian cancer base combination chemotherapy base platinum salt surgery whose quality major prognostic factor . A meta-analysis retrospective series show every 10 % increase complete cytoreduction rate increase 5.5 % overall survival time ( Markman et al , 2001 ) . Currently , recognize best chance survival confer patient whose initial surgical residue zero ( Harter et al , 2009 ) . However , even macroscopically complete surgery whatever type systemic chemotherapy , peritoneal recurrence remain high 75 % . To reduce recurrence , therapeutic approach administer chemotherapy intraperitoneally . The intraperitoneal chemotherapy consist administer drug directly peritoneal cavity . Alberts et al , 1996 Armstrong et al , 2006 compare efficacy term survival intraperitoneal chemotherapy accord method conventional systemic chemotherapy . Alberts report significant improvement median overall survival . Armstrong show addition decrease risk recurrence . It must remember : - The establishment intra-abdominal catheter always ensure complete flow drug peritoneal cavity ( major postoperative adhesion ) . - There may problem catheter become block require local treatment ; problem cause abdominal pain whose care difficult . Thus almost half patient fail get six course intraperitoneal chemotherapy . Thus , investigator propose estimate flow intraperitoneal chemotherapy IP peritoneal scintigraphy , use radiotracer ( nanocis® ) . The investigator hypothesize movement colloid peritoneal cavity similar circulation chemotherapy within peritoneal cavity ( From Forni et al , 1993 , Varia et al , 2003 , Young et al , 2003 , Dawson et al , 2011 ) . The accumulation radiotracer correlate abdominal pain site describe patient well peritoneal recurrence site find monitoring .</brief_summary>
	<brief_title>Study Isotopic Distribution Intraperitoneal Chemotherapy Peritoneal Carcinomatosis Ovarian Origin</brief_title>
	<detailed_description>Epithelial ovarian cancer fifth lead cause female cancer lead cause death among gynecological cancer ( Alberts et al , 2002 ) . The treatment advance ovarian cancer base combination chemotherapy base platinum salt surgery whose quality major prognostic factor . A meta-analysis retrospective series show every 10 % increase complete cytoreduction rate increase 5.5 % overall survival time ( Markman et al , 2001 ) . Currently , recognize best chance survival confer patient whose initial surgical residue zero ( Harter et al , 2009 ) . However , even macroscopically complete surgery whatever type systemic chemotherapy , peritoneal recurrence remain high 75 % . To reduce recurrence , therapeutic approach administer chemotherapy intraperitoneally . The intraperitoneal chemotherapy consist administer drug directly peritoneal cavity frequency relate systemic chemotherapy ( every 3 week ) . Alberts et al , 1996 Armstrong et al , 2006 compare efficacy term survival intraperitoneal chemotherapy accord method conventional systemic chemotherapy . Alberts report significant improvement median overall survival ( 49 vs 41 month ) . Armstrong show addition decrease risk recurrence . It must remember : - The establishment intra-abdominal catheter always ensure complete flow drug peritoneal cavity ( major postoperative adhesion ) . - There may problem catheter become block require local treatment ; problem cause abdominal pain whose care difficult . Thus almost half patient fail get six course intraperitoneal chemotherapy . Thus , investigator propose estimate flow intraperitoneal chemotherapy IP peritoneal scintigraphy , use radiotracer ( nanocis® ) . The investigator hypothesize movement colloid peritoneal cavity similar circulation chemotherapy within peritoneal cavity ( From Forni et al , 1993 , Varia et al , 2003 , Young et al , 2003 , Dawson et al , 2011 ) . The accumulation radiotracer correlate abdominal pain site describe patient well peritoneal recurrence site find monitoring .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Performance Status 02 PNN &gt; 1.5.109 / L ( without add GCSF ) Plaquettes &gt; 100 . 109 / L Bilirubine inferior equal 1.5 time upper normal value ( VNS ) ASAT And ALT inferior equal 2.5 upper normal value ( VNS ) Alkaline Phosphatase inferior equal to2.5 upper normal value ( VNS ) Clairance Creatinine &gt; 60ml / min Normal Ionogramme PTT &lt; 1.5 time upper normal value ( VNS ) ( heparin , accept lovenox anticoagulant ) PT / INR inferior equal 1.5 upper normal value ( VNS ) ( INR 2 3 , patient receives stabilize dose Warfarin ) Patient operate first line without macroscopic residual ovarian cancer primary peritoneal tubal stage IIIC IV peritoneal pleural Minimum Required surgery : hysterectomy , oophorectomy , pelvic lymphadenectomy paraaortic omentectomy Patient require adjuvant chemotherapy Compulsory affiliation social security scheme . Obtaining informed consent writing , sign date . Patient cognitive psychiatric disorder . Patient deprive liberty court administrative . Patient direction achievement chemotherapy Concomitant treatment drug test , participation another therapeutic clinical trial within 30 day Pregnant woman Nursing woman Patient recognize hypersensitivity cisplatin platinumcontaining product Patient hypersensitivity recognize paclitaxel excipients Patient must vaccinate yellow fever Patient take phenytoin prophylactic purpose Patient hear impairment Patient hepatic impairment Patient renal impairment Sensory motor Neuropathies &gt; grade 1 ( CTCAE ) Hépatite Or severe infection require parenteral antibiotic Serious nonhealing wound ulcer , bone fracture Fistule Abdominal gastrointestinal perforation , intraabdominal abscess 28 day precede intraperitoneal chemotherapy Clinical Symptômes , gastrointestinal obstruction sign / require hydration / parenteral nutrition Patientes Has currently inflammatory bowel disease Active bleeding medical condition carry high risk bleeding ( eg , know coagulation disorder , coagulopathy , tumor large vessel ) Cerebrovascular accident ( CVA ) transient ischemic attack , subarachnoid hemorrhage last 6 month Disease clinically significant cardiovascular , include : uncontrolled hypertension , define systolic blood pressure &gt; 150mmHg diastolic &gt; 90mmHg myocardial infarction unstable angina within last 6 month NYHA class IIIV congestive heart failure serious cardiac arrhythmia require treatment : asymptomatic atrial fibrillation control ventricular rate supraventricular tachycardia control medication authorize asymptomatic peripheral vascular disease ≥ Grade 2 ( CTCAE ) ( brief [ le 24 hour ] ischemia episode manage nonsurgically without permanent deficit ) Antecedents Hemorrhage stroke ( stroke ) , transient ischemic attack , subarachnoid last 6 month Major Surgery within 28 day prior inclusion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>intraperitoneal chemotherapy</keyword>
</DOC>